Document Detail


Long-term complications of platinum-based chemotherapy in testicular cancer survivors.
MedLine Citation:
PMID:  17848741     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to describe the rates of cardiovascular and other medical complications related to the use of platinum-based chemotherapy in American testicular cancer survivors. The study sample consisted of 143 eligible long-term testicular cancer survivors. Participants were interviewed, their medical records were reviewed, and blood was obtained for cholesterol measurement during their follow-up visit. The mean follow-up time was 8.4 yr, and their mean age at follow-up was 41.2 yr; 72.7% had had non-seminoma, and 82.5% had received platinum-based chemotherapy. Hypertension rates in the platinum-treated group increased significantly from baseline to follow-up; however, once adjusted for blood pressure measurement (undiagnosed hypertension), no such increase was seen, and hypertension rates were already higher than national estimates at baseline in all groups. At the follow-up visit, the rates of hyperlipidemia (adjusted for measured cholesterol level) in both platinum- and non-platinum-treated groups (28.4% and 37.5%, respectively) were higher than national estimates (16.9%). Rates of coronary artery disease were higher in those who had received platinum and radiation (11.1%) than in those who had received platinum alone (4.3%), but this difference was not statistically significant. As suggested by previous studies, platinum-based chemotherapy may be associated with hypertension, hyperlipidemia, and coronary artery disease. However, our data suggest that undiagnosed hypertension and hyperlipidemia may be significant confounders, and we also observed a trend toward lower testosterone levels in participants who experienced cardiovascular complications.
Authors:
J H Oh; D D Baum; S Pham; M Cox; S T Nguyen; J Ensor; I Chen
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  24     ISSN:  1357-0560     ISO Abbreviation:  Med. Oncol.     Publication Date:  2007  
Date Detail:
Created Date:  2007-09-12     Completed Date:  2007-12-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  175-81     Citation Subset:  IM    
Affiliation:
Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, Unit 437, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030-4009, USA. jhoh@mdanderson.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Antineoplastic Agents / adverse effects*,  therapeutic use
Cisplatin / adverse effects*,  therapeutic use
Coronary Artery Disease / chemically induced
Follow-Up Studies
Humans
Hyperlipidemias / blood,  chemically induced*
Hypertension / chemically induced*
Male
Middle Aged
Renal Insufficiency / chemically induced
Risk Factors
Survivors
Testicular Neoplasms / blood,  drug therapy*
Testosterone / blood
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 15663-27-1/Cisplatin; 58-22-0/Testosterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression of c-kit proto-oncogene product in breast cancer tissues.
Next Document:  Inhibitory effects of a nutrient mixture on human testicular cancer cell line NT 2/DT matrigel invas...